# Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

> **NCT01032850** · PHASE2 · TERMINATED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 15 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib & Capecitabine

## Key facts

- **NCT ID:** NCT01032850
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2012-05
- **Final completion:** 2017-08
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Low accrual rate
- **Last updated:** 2021-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01032850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01032850, "Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01032850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*